国金证券股份有限公司 关于厦门特宝生物工程股份有限公司 使用自有资金支付募投项目所需资金并以募集资金等额 置换的核查意见 国金证券股份有限公司（以下简称"保荐机构"）作为厦门特宝生物工程股份 有限公司（以下简称"公司"或"特宝生物"）首次公开发行股票并在科创板上市 的保荐机构，根据《证券发行上市保荐业务管理办法》《上海证券交易所科创板股 票上市规则》《上海证券交易所科创板上市公司自律监管指引第1号——规范运作》 等相关规定，对特宝生物使用自有资金支付募投项目所需资金并以募集资金等额置 换的事项进行了核查，核查情况及核查意见如下： 一、募集资金基本情况 公司首次公开发行股票募集资金净额用于以下募投项目： 序号 项目名称 投资总额 拟使用募集资金金额注 1 蛋白质药物生产改扩建和研发中心建 设项目 38,653.65 19,940.09 2 新药研发项目 28,867.56 10,168.54 3 慢性乙型肝炎临床治愈研究项目 2,936.00 2,936.00 合计 70,457.21 33,044.63 单位：万元 注：根据募投项目建设进展，为提高募集资金使用效率，公司于 2023 年 12 月 6 日分别召 ...

证券代码：688278 证券简称：特宝生物 公告编号：2025-022 厦门特宝生物工程股份有限公司 关于调整公司组织架构的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 厦门特宝生物工程股份有限公司（以下简称"公司"）于2025年7月15日召开 第九届董事会第九次会议，审议通过了《关于调整公司组织架构的议案》。 为更好地适应公司战略布局和业务发展的实际需求，提升管理水平和运营效率， 保障业务持续稳定发展，公司对组织架构进行了调整优化。本次组织架构调整是对 公司内部管理机构的调整，不会对生产经营活动产生重大影响，董事会同时授权公 司经营管理层负责组织架构调整后的具体实施等相关事宜。调整后的公司组织架构 图详见附件。 特此公告。 厦门特宝生物工程股份有限公司 董事会 2025 年 7 月 16 日 附件： 厦门特宝生物工程股份有限公司组织架构图 ...

证券代码：688278 证券简称：特宝生物 公告编号：2025-023 厦门特宝生物工程股份有限公司 关于使用自有资金支付募投项目所需资金并以募集资金 等额置换的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 厦门特宝生物工程股份有限公司（以下简称"公司"）于2025年7月15日分别 召开第九届董事会第九次会议、第九届监事会第六次会议，审议通过了《关于使用 自有资金支付募投项目所需资金并以募集资金等额置换的议案》，同意公司在募集 资金投资项目（以下简称"募投项目"）实施期间，根据实际情况先行使用自有资 金支付募投项目所需资金，在履行内部相关审批程序后以募集资金等额置换，该部 分等额置换资金视同募投项目已使用资金。公司监事会发表了明确的同意意见，保 荐机构国金证券股份有限公司对本事项出具了明确的核查意见，现将具体情况公告 如下： 一、募集资金基本情况 根据中国证券监督管理委员会《关于同意厦门特宝生物工程股份有限公司首次 公开发行股票注册的批复》（证监许可〔2019〕2828 号）核准，并经上海证券交易 所"自律监管决定书 ...

二、监事会会议审议情况 （一）审议通过《关于使用自有资金支付募投项目所需资金并以募集资金 等额置换的议案》 监事会认为：公司使用自有资金支付募投项目所需资金并以募集资金等额 置换，有利于提高公司资金的使用效率，不会影响募投项目的正常实施，也不 存在变相改变募集资金用途的情形，相关审批手续符合法律法规及规范性文件 的规定。综上，监事会同意公司使用自有资金支付募投项目所需资金并以募集 资金等额置换。 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 厦门特宝生物工程股份有限公司（以下简称"公司"）第九届监事会第六 次会议于 2025 年 7 月 15 日以现场结合通讯表决的方式召开。本次会议已于 2025 年 7 月 4 日以邮件方式通知了全体监事，本次会议由监事会主席刘军先生 主持，会议应到监事 3 人，实到监事 3 人。本次会议的召开符合《公司法》及 《公司章程》等有关规定，会议决议合法、有效。 表决结果：3 票同意，0 票反对，0 票弃权。 证券代码：688278 证券简称：特宝生物 公告编号：20 ...

Core Viewpoint - The Shanghai Stock Exchange Science and Technology Innovation Board Biopharmaceutical Index has shown strong performance, with significant increases in constituent stocks, indicating a positive trend in the biopharmaceutical sector [1][3]. Market Performance - As of July 11, 2025, the Biopharmaceutical Index rose by 1.23%, with notable gains from stocks such as Yifang Biotech (+10.31%), Shouyao Holdings (+8.34%), and Te Bao Biotech (+7.18%) [1]. - The Jiashi Science and Technology Medicine ETF (588700) also increased by 1.14%, marking its third consecutive rise [1]. Liquidity and Trading Volume - The Jiashi Science and Technology Medicine ETF recorded a turnover rate of 9.54% and a trading volume of 21.11 million yuan [3]. - Over the past month, the ETF has maintained an average daily trading volume of 33.32 million yuan, ranking first among comparable funds [3]. Fund Growth and Performance - In the last two weeks, the Jiashi Science and Technology Medicine ETF's scale increased by 17.56 million yuan, leading among comparable funds [3]. - The ETF's net value has risen by 37.70% over the past year, with a maximum single-month return of 23.29% since its inception [3]. Top Holdings - As of June 30, 2025, the top ten weighted stocks in the Biopharmaceutical Index accounted for 50.3% of the index, including companies like United Imaging Healthcare, BeiGene, and Huatai Medical [3][5]. Policy Support and Market Outlook - Recent policy documents have been released to support the high-quality development of innovative drugs, highlighting government backing for the sector [6]. - The number of innovative drugs in development in China has reached over 4,000, representing approximately 30% of the global total [5][6].

Group 1 - The core viewpoint highlights the significant growth and performance of the Kexin Pharmaceutical ETF managed by Jiashi, with a notable increase in trading volume and fund size [2] - As of July 9, the Kexin Pharmaceutical ETF achieved a daily average trading volume of 34.95 million yuan over the past month, ranking first among comparable funds [2] - The fund's size increased by 16.76 million yuan in the past two weeks, also ranking first among comparable funds [2] - The ETF saw a total inflow of 12.84 million yuan over the last ten trading days, indicating strong investor interest [2] - The net value of the Kexin Pharmaceutical ETF rose by 36.83% over the past year, showcasing its strong performance [2] Group 2 - The top ten weighted stocks in the Shanghai Stock Exchange Science and Technology Innovation Board Biopharmaceutical Index account for 50.3% of the index, with leading companies including United Imaging Healthcare and BeiGene [2][4] - On July 9, Shanghai Pharmaceuticals announced an expected net profit of 4.45 billion yuan for the first half of 2025, representing a year-on-year increase of approximately 52% [4] Group 3 - Short-term market expectations for overseas transactions in innovative drugs are high, leading to a continuous rise in valuations [5] - China's innovative drug research and development capabilities are competitive globally, and the trend of innovative drugs going overseas is expected to persist [5] - The commercial health insurance sector in China is anticipated to see significant growth in premium income and payout rates, becoming an important source of funding for innovative drugs [5]

证券代码：688278 证券简称：特宝生物 公告编号：2025-021 厦门特宝生物工程股份有限公司 关于持股 5%以上股东协议转让部分股份完成过户登记 的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 厦门特宝生物工程股份有限公司（以下简称"公司"）于 2025 年 7 月 3 日收 到持股 5%以上股东通化东宝药业股份有限公司（以下简称"通化东宝"）的通知， 获悉其协议转让公司部分股份事宜已完成过户登记手续，具体情况如下： 一、本次协议转让基本情况 2025 年 5 月 22 日，通化东宝与西藏信托有限公司（代表"西藏信托-金桐 35 号集合资金信托计划"）（以下简称"西藏信托"）签署了《股份转让协议》， 约定通过协议转让方式将其持有的占公司总股本 5.70%的 23,187,600 股公司无限 售条件流通股，以 56.12 元/股的价格转让给西藏信托，具体内容详见公司于 2025 年 5 月 23 日在上海证券交易所网站（www.sse.com.cn）披露的《关于持股 5%以上 股东协议转让部分股份暨权益变动的 ...

Group 1 - The core point of the news is that the main funds in the Shanghai and Shenzhen markets experienced a net inflow of 7.138 billion yuan, with the Sci-Tech Innovation Board seeing a net outflow of 323 million yuan [1] - A total of 233 stocks saw net inflows, while 355 stocks experienced net outflows [1] - On the Sci-Tech Innovation Board, 452 stocks rose, with one stock, Tai Lingwei, hitting the daily limit, while 126 stocks declined [1] Group 2 - The top three stocks with the highest net inflow of main funds are: Han's Laser with 362 million yuan, SMIC with 349 million yuan, and Tai Lingwei with 107 million yuan [2] - The stock with the highest net outflow was Guangda Special Materials, which saw a net outflow of 158 million yuan despite a price increase of 2.91% [1][2] - There are 62 stocks that have seen continuous net inflows for more than three trading days, with Sanyou Medical leading at 10 consecutive days [2] Group 3 - The main funds' inflow ranking shows that Han's Laser had an inflow rate of 6.40% and a price increase of 0.64% [2] - Other notable stocks include Kingsoft Office with an inflow of 101 million yuan and a price increase of 3.87%, and Wealth Trend with an inflow of 100 million yuan and a price increase of 17.84% [2] - A total of 114 stocks experienced continuous net outflows, with Bohui Technology leading at 24 consecutive days of outflow [2]

Core Viewpoint - The innovative pharmaceutical sector is experiencing a resurgence, driven by improved fundamentals, supportive policies, and increased market interest, particularly in the A-share and Hong Kong markets [1][3][12]. Group 1: Market Performance - The pharmaceutical sector has shown strong performance this year, with a notable rebound starting from April 9, despite recent pullbacks [1]. - The innovative drug segment in A-shares and Hong Kong stocks has continued to strengthen, indicating a recovery after four years of adjustment [1][3]. - The total amount of business development (BD) transactions for innovative drugs is projected to rise significantly, from $8.4 billion in 2020 to $51.9 billion in 2024 [4]. Group 2: Policy and Industry Trends - The policy environment has shifted from cost control to encouraging innovation, providing strong support for the development of innovative drugs [3]. - The number and quality of innovative drug products in China have significantly improved, leading to increased interest from foreign pharmaceutical companies [3][5]. - The penetration rate of innovative drugs in China is expected to rise, with current levels at around 20%, compared to 70%-80% in the U.S. [5]. Group 3: Investment Opportunities - Fund managers are optimistic about the future of innovative drugs, emphasizing the importance of technology and growth attributes in the sector [6]. - Investment strategies include focusing on high-quality companies, innovative drug leaders, and traditional pharmaceutical companies transitioning to innovative drugs [7][8][9]. - Investors can consider actively managed pharmaceutical funds or industry-themed ETFs to gain exposure to the innovative drug market [10][12]. Group 4: Fund Performance - Several funds managed by 工银瑞信 have demonstrated strong performance, ranking highly in their respective categories over various time frames [13][15]. - The 工银港股通创新药ETF has seen significant inflows, reflecting market preference for innovative drug companies [11].

Group 1: Industry Overview - The production of pediatric medications has historically faced challenges, including a lack of manufacturers, limited varieties, and insufficient suitable formulations, referred to as the "three shortages" [1] - Recent government policies have been introduced to encourage and support the research and production of pediatric medications [1][9] - The approval of pediatric medications has been increasing, with 106 new pediatric drug varieties approved in 2024, along with 35 additional varieties expanding pediatric indications [9] Group 2: Challenges in Pediatric Medication - There are significant challenges in pediatric drug development, including difficulties in recruiting child patients for clinical trials and determining appropriate dosages and administration methods [8][10] - The issue of "disease waiting for drugs" and the prevalence of off-label use of adult medications for children pose risks to pediatric medication safety [8][10] Group 3: Importance of Education and Awareness - There is a need for enhanced public awareness and education regarding children's growth and development, as many parents still hold misconceptions that prevent timely medical consultations [2][3][4] - Strengthening educational efforts among healthcare professionals and the public is crucial for improving the diagnosis and treatment of growth-related issues in children [3][4][7] Group 4: Innovations in Pediatric Medication - Companies are increasingly focusing on the pediatric growth and development sector, with innovations such as long-acting growth hormones that reduce the frequency of administration from daily to weekly [5][6] - The introduction of user-friendly devices, such as smart electronic injection pens, aims to improve the safety and comfort of pediatric patients during treatment [6] Group 5: Future Directions - There is a call for further research into various causes of growth disorders and the development of specific treatment plans for rare syndromes and genetic defects [7] - Collaboration between enterprises and public organizations is essential to enhance the accessibility and precision of pediatric medications, ensuring that children receive timely and appropriate treatment [10]